AskBiography Logo   Latest News  Follow Us on Twitter  Follow Us on Google Buzz  Became Fan - Facebook  Subscribe to RSSRSS   Bookmark and Share

Merck & Co.

Company nameMerck & Co., Inc.
(Merck Sharp & Dohme (MSD) outside the United States and Canada)
Company typePublic
IndustryPharmaceuticals
Founded1891 as a subsidiary of Merck KGaA
1917 as an independent company
HeadquartersWhitehouse Station, New Jersey, United States
Key peopleRichard T. Clark
(Chairman)
Kenneth Frazier
(President and CEO)
ProductsGardasil
Singulair
Propecia/Proscar
Zocor Vioxx Fosamax
See more complete products listing.
Revenue(+) US$ 45.987 billion (2010)
Operating income(-) US$ 1.653 billion (2010)
Net income(-) US$ 861 million (2010)
Total assets(-) US$ 105.781 billion (2010)
Total equity(-) US$ 56.805 billion (2010)
Employees94,000 (2010)

     Home | Company | Merck and Company





Merck & Co., Inc. (Nyse - MRK), also known as Merck Sharp & Dohme or MSD outside the United States and Canada, is one of the largest pharmaceutical companies in the world. The Merck headquarters is located in Whitehouse Station, New Jersey, an unincorporated area in Readington Township. The company was established in 1891 as the United States subsidiary of the German company now known as Merck KGaA. In common with many other German assets in the United States, Merck & Co. was confiscated in 1917 during World War I and then set up as an independent company. Currently, it is one of the seven largest pharmaceutical companies in the world both by market capitalization and revenue.

Merck & Co. or MSD describes itself as a "a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures." The Merck Company Foundation has distributed over $480 million to educational and non-profit organizations since it was founded in 1957.

Merck publishes The Merck Manuals, a series of medical reference books. These include the Merck Manual of Diagnosis and Therapy, the world's best-selling medical textbook, and the Merck Index, a collection of information about chemical compounds.

Merck and Company Video

Representatives from AIDS Healthcare Foundation protested at the JP Morgan Health Conference (Jan 12, 2010) due to the steep price increase by Merck and Co. Pharmaceuticals in it's key HIV/AIDS drug, Isentress. The drug was recently approved by the FDA in Oct 2007 as a salvage therapy for HIV patients who are resistant to other AIDS drugs but has recently been approved for first-line therapy as well - thus greatly expanding the US market for the drug and making Mercks Isentress the most expensive first line treatment. For more information, visit www.aidshealth.org
1.03 min. | 4.5 user rating		 Die Sorgen um den schwer angeschlagenen Staatshaushalt Griechenlands haben die Finanzmärkte bereits heftig bewegt. Wie geht es weiter und welche Auswirkungen hat dies auf das Währungspaar Euro / US-Dollar? Dr. Josef Kaesmeier, Chefvolkswirt der Privatbank Merck Finck & Co. verrät im Interview seine Einschätzungen und erklärt, warum Anleger in Schwellenländer investieren sollten.
3.58 min. | 4.5 user rating		 The 2011 annual Harry Middleton Lectureship, Sponsored by the LBJ Foundation presents: Former President Jimmy Carter. Jimmy Carter spoke with LBJ Library Director Mark Updegrove. Major topics of the evening included analysis of current events in the Middle East and Jimmy Carter's pre- and post- presidency career. Part IV of the discussion focuses on the Carter Center and the years immediately following Jimmy Carter's presidency. Jimmy Carter talks about the Carter Center's work in alleviating the affects of Guinea Worm and River Blindness. Guinea worm cases have existed in Sub-Sahara Africa, Pakistan, Yemen, and India. Merck & Co. provided medicine for the treatment of River Blindness, an arrangement Jimmy Carter secured through working with Roy Vagelos. Jimmy Carter talks about his experience as a professor at Emory University and recounts the story behind the "Jimmy Carter killer rabbit incident". He states that Harry Truman is his favorite president and refers to his time in the Navy.
15.00 min. | 0 user rating		 US stock futures are trading higher after European leaders said on Monday that Greece will have another month to come up with a plan to reduce its deficit, but again pledged to support the debt-burdened country. Throughout the week, earnings and economic reports will likely be scrutinized for signs of continued US economic improvement, though concerns about overseas growth remain. In corporate news, Kraft Foods (NYSE:KFT)reported Q4 EPS of $0.48, besting consensus estimates of $0.45. Revenues for the quarter rose 3.2% year-over-year to $11.0 billion, just shy of consensus estimates of $11.1 billion. Merck & Co. (NYSE:MRK) reported Q4 EPS of $0.79, ex-items, in line with consensus estimates. Revenues for the quarter rose 67.3% year-over-year to $12.2 billion, topping consensus estimates of $9.07 billion. The Dow Jones Industrial Average (DJI) futures are trading 70.86 points above fair value, the S&P500 (INX) futures are trading 8.89 points above fair value, and the Nasdaq Composite (IXIC) futures are trading 10.19 points above fair value.
1.40 min. | 0 user rating		 United Nations, New York, 13 April 2011 - "I think the private sector can add a tremendous unbiased view to the education system," says Ms. Theresa McCoy, Manager, Education Grant Programmes, Office of Corporate Philanthropy, Merck & Co., Inc. Ms. McCoy answers the following questions: What added value can the private sector bring to education policy-making and delivery? Are the education systems adapted to the needs of today's economy? Is there a role for the private sector to help close the global teacher gap? Ms. McCoy was interviewed prior the special event of the Economic and Social Council (ECOSOC), "Partnering with the philanthropic community to promote education for all" on 28 February 2011. This event was one of the preparatory events for the 2011 ECOSOC Annual Ministerial Review (AMR) on "implementing the internationally agreed goals and commitments in regard to education", and was organized by the Department of Economic and Social Affairs (UNDESA), in collaboration with the United Nations Children's Fund (UNICEF), United Nations Educational, Scientific and Cultural Organization (UNESCO), the United Nations Office for Partnerships (UNOP), and the Committee Encouraging Corporate Philanthrophy (CECP). The key objective of the special event was to increase focus on issues central to the achievement of education for all, through: (i) broadening of the range of stakeholders involved in the work of ECOSOC, as well as increasing the awareness amongst the philanthropic <b>...</b>
1.78 min. | 2.6 user rating
GIA Conference New York 2010 Taking Strategic Market Intelligence to the Next Level Date: 8-10 November 2010 Venue: The Park Central Hotel, New York, USA To sign up now, simply send an email to events(at)globalintelligence.com Learn how leading companies apply the key success factors of World Class Market Intelligence to improve their competitive advantage. Understand how to integrate your Market Intelligence program with key decision making processes. Gain insights into Market Intelligence trends towards 2015, and what you need to know about Market Intelligence in emerging markets. Best practices will be shared by leading global companies, such as Best Buy, Cintas, Cisco Systems, Genesys, General Electric, IBM, Johnson Controls, Merck & Co., Monster Worldwide, Philips, The Procter & Gamble Company and more. In addition to case presentations, the GIA Conference will include interactive workshops and panel discussions on current hot topics in the area of Strategic Market Intelligence. The GIA Conference will focus strictly on delivering best-in-class educational program. There will be no exhibition area or vendor/sponsor product presentations. For more information please visit our website www.globalintelligence.com/events/gia-conference-usa-nov-2010/
0.98 min. | 0 user rating		 Shares of Merck & Co. (MRK) are higher after the company announced this morning that it is teaming up with PAREXEL International (PRXL) to provide a range of regulatory and clinical services to Merck BioVentures, a division of Merck that specializes in delivering high quality biosimilars to patients. The move is the latest indication that pharmaceutical companies and biotech companies are interested in the nascent market of biosimilar medications. Merck shares are up 0.14% while Parexel is up almost 3%.
0.67 min. | 5.0 user rating		 Today drugmaker Merck & Co. posted a 12 percent drop in second-quarter profits, then Caterpillar's second-quarter profit tumbled, and CIT Group said in a regulatory filing that it might still have to file for bankruptcy protection. Up in Sacramento, legislative leaders began lobbying rank-and-file members to vote for a compromise to close the budget shortfall - a contentious vote is expected Thursday. Over in Washington Fed Chairman Bernanke ran into skepticism about expanding the Fed's duties to police big financial companies - considering they failed to spot problems that led to the financial crisis in the first place. But some good news - JPMorgan Chase Chief Executive Jamie Dimon made a $2.2 million pretax profit by exercising stock options and then selling most of the resulting shares of the second-largest US bank.
1.17 min. | 0 user rating		 At the Advancing Development by Design | Market-Based Solutions Breakout #1 of the 2010 CGI Annual Meeting, Debra Dunn announces a new CGI commitment Bridging Health & Education Programs for Young Children by Geralyn Ritter, VP, Global Public Policy & Corporate Responsibility, Merck & Co., Inc.
1.88 min. | 0 user rating		 Health care shares are flat to higher in mid-day trading while Merck & Co. (MRK) gets its first state-court win in litigation concerning its Fosamax drug. In mid-session news, shares of Eli Lilly (LLY) are higher after the Financial Times reported that the drug maker is looking to raise up to $750 million through three funds that will share drug development costs with external researchers and venture capitalists. The move is a part of an effort by drug companies to discover new ways to improve high failure rates and costs of drugs, the report said. Meanwhile, shares of Merck are down as the company said that it won the first state court trial over its Fosamax osteoporosis drug, which was blamed for osteonecrosis of the jaw. Merck previously won two of three cases that went to jury verdicts in Manhattan federal court.
1.00 min. | 0 user rating

Latest News : Merck and Company : Tweet this RSS

Want to Merck and Company latest news on your twitter account???   sign in with twitter
Merck and Company     sign in with twitter   ||  Company     sign in with twitter   ||  Economy     sign in with twitter
With Sun Pharma-Merck striking JV, why is SPARC shining? - Moneycontrol.com Tweet this news
Moneycontrol.com--SPARC has seen double digit gains today after Sun Pharma the parent company said that -Merck & Co- will contribute to its technology through a Joint Venture (JV) wherever necessary. Sun Pharma is touted as one of the fastest grow - Date : Wed, 13 Apr 2011 09:20:43 GMT+00:00
Inspire Pharmaceuticals Investor Sues Over Merck Acquisition - Bloomberg Tweet this news
Bloomberg--An Inspire Pharmaceuticals Inc. (ISPH) shareholder filed a lawsuit claiming -Merck & Co-.'s $430 million offer for the company is inadequate. Company directors breached their fiduciary duties by accepting ... - Date : Tue, 12 Apr 2011 17:09:44 GMT+00:00
Merck Serono: Data on Parkinson's Disease Investigational Drug Safinamide to ... - PR Newswire UK (press release) Tweet this news
PR Newswire UK (press release)--Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the US subsidiary -Me - Date : Wed, 13 Apr 2011 05:06:58 GMT+00:00
FDA Clears Merck's Cancer Drug - FavStocks Tweet this news
FavStocks--By Zacks Research on 04/13/2011 - 8:00 am PDT -- Business News Recently, the US Food and Drug Administration (FDA) cleared -Merck & Co-., Inc.'s (MRK) skin cancer (melanoma) drug, Sylatron (peginterferon alfa-2b). The once-weekly i - Date : Wed, 13 Apr 2011 15:01:38 GMT+00:00
Merck gets FDA nod for skin cancer drug - Reuters Tweet this news
Reuters--April 11 (Reuters) - -Merck & Co- Inc said the US health regulator approved its drug to treat skin cancer in patients with node-positive melanoma, following removal of the affected part. Merck's drug Sylatron, which is delivered by a - Date : Mon, 11 Apr 2011 22:15:11 GMT+00:00
Merck & Co, Inc Declares Update for Phase II/III Clinical Trial Evaluating ... - Galaxy Stocks Tweet this news
Galaxy Stocks---Merck & Co-, Inc NYSE:MRK announced today that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the i - Date : Mon, 11 Apr 2011 12:50:28 GMT+00:00
Merck plans job cuts - Danville News Tweet this news
Danville News--By Marcia Moore and and Robert Stoneback The Daily Item RIVERSIDE � Seven months after -Merck- bought back the plant it sold just a few years earlier, -company- officials Tuesday announced plans to sell off one product line and outsource ot - Date : Wed, 13 Apr 2011 10:25:41 GMT+00:00
Trade Alert - Merck High Volume - TradersHuddle.com Tweet this news
TradersHuddle.com---Merck & Co-., Inc. (NYSE:MRK), the global pharmaceutical company that develops, manufactures, and markets a broad range of human and animal health products. Merck's products include Zocor for treatment of elevated choleste - Date : Mon, 11 Apr 2011 15:58:43 GMT+00:00
Merck & Co. to Pick Up Inspire Pharmaceuticals for $430M - Genetic Engineering News Tweet this news
Genetic Engineering News---Merck & Co-., known as MSD outside the US and Canada, is acquiring Inspire Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. The transaction has a total ca - Date : Tue, 05 Apr 2011 14:36:28 GMT+00:00
Merck Sharpe and Dohme returns betrixaban rights to Portola - Zenopa Tweet this news
Zenopa---Merck- Sharpe and Dohme is to return the rights to the atrial fibrillation (AF) treatment betrixaban to its collaborative partner Portola Pharmaceuticals. The -company- is transferring rights to the treatment, which is designed to prevent strokes - Date : Tue, 29 Mar 2011 10:16:42 GMT+00:00

Dow Jones Industrial Average components

Current3M * Alcoa * American Express * AT&T * Bank of America * Boeing * Caterpillar * Chevron * Cisco Systems * The Coca-Cola Company * DuPont * ExxonMobil * General Electric * Hewlett-Packard * The Home Depot * Intel * IBM * Johnson & Johnson * JPMorgan Chase * Kraft Foods * McDonald's * Merck & Co. * Microsoft * Pfizer * Procter & Gamble * The Travelers Companies * United Technologies Corporation * Verizon Communications * Wal-Mart * The Walt Disney Company
Selected
former		Altria Group * American International Group * American Telephone & Telegraph * American Tobacco Company * Bethlehem Steel * Citigroup * Colorado Fuel and Iron * Eastman Kodak * General Foods * General Motors * Goodyear Tire and Rubber Company * Honeywell * International Harvester * International Paper * Johns-Manville * Nash Motors * Navistar International * North American Company * Owens-Illinois * Sears, Roebuck and Company * Union Carbide * United States Rubber Company * U.S. Steel * F. W. Woolworth Company



Privacy | Sitemap | Micra Hosting | USA Yellow Pages